Search in the Abstract Database

Abstracts Search 2019

P098 Role of serum lysol oxidase like 2 in Crohn's disease and modulation to biological treatment

M. J. Garcia Garcia*1, A. Garcia Blanco2, B. Castro Senosiain1, M. Pascual Mato1, C. Del Pozo Calzada1, J. Crespo Garcia1, M. Rivero Tirado1

1Marques De Valdecilla Universitary Hospital, Gastroenterology, Santander, Spain, 2Biotechnology and Biomedicine Institute of Cantabria (IBBTEC), Santander, Spain


Lysyl oxidase-like 2 (LOXL-2) expression at the level of the mucosa is elevated in diseases with fibrotic component, and also, has been involved in the biogenesis of connective tissue after the activation of the signalling pathway of TGF β-1. The aim of our study is the evaluation of serum levels of LOXL-2 in patients with Crohn's disease (CD) and assess the variability of the levels after the start of biological treatments.


We performed a cross-sectional study to determine the serum levels of LOXL-2 by enzyme-linked immunosorbent assay (ELISA) in patients with CD defined according to the European Crohn's and Colitis Organisation (ECCO). For this, 24 patients with Crohn's disease and 24 healthy controls were analysed matched by age and sex. The baseline characteristics of the patients were collected and biochemical parameters were also measured at baseline and 6 months after the start of the biological therapy. The patients were classified according to the response in responders and no responders.


LOXL 2 levels were higher in patients with CD (72.81 pg/ml (SD 24.65)) compared with healthy controls (31.40 pg/ml (SD 19.39)) in a significant way (p = 0 0.0001). No significant differences were observed related to smoking, age or years of disease evolution. Higher levels were observed in those who required surgery prior to inclusion in the study with regards to those without surgery [(80.53 pg/ml (SD 22.66) vs. 60.53 pg/ml (SD 22.23) (p = 0.02]. Regarding the characteristics of Crohn's disease, no significant differences were found in LOXL-2 levels in relation to behaviour or location, although a tendency of higher levels of LOXL-2 was observed in patients with intestinal involvement respect to colonic involvement. (78.92 pg/ml (SD 24.83) vs. 55.19 pg/ml (SD 13.14)). As found in those patients with penetrating or stenosing behaviour with regards to inflammatory (78.92 pg/ml (SD 32.08) vs. 60.53 pg/ml (SD 20.03)). No differences were observed in the levels according to the response 6 months after starting biological treatment. A positive correlation was observed between albumin and haemoglobin levels with LOXL2 levels (r = 0.45, r = 0.54, p < 0.05) while a negative correlation was observed with the Harvey Index (r = −0.51, p = <0.05). A positive correlation was observed with faecal calprotectin at 6 months after inclusion (r = 0.58, p < 0.05)


Serum levels of LOXL2 were elevated in patients with Crohn's disease and were significantly higher than the healthy control group. Patients who required previous surgery showed higher levels than those without surgery. More studies are needed to corroborate these results with a larger sample size to know the real involvement of LOXL2 in CD.